Cereius has raised $7.0M in total across 1 funding round.
Cereius's investors include BDC Venture Capital, Domain Associates, Forbion, Mission BioCapital, RTW Investments.
Cereius, Inc. is a preclinical-stage biopharmaceutical company that developed innovative next-generation targeted radiodiagnostics and radiotherapeutics for cancer patients, particularly focusing on solid tumor brain metastasis.[1][2] It built a modular conjugation chemistry platform using unique radiolabeling chemistries to enhance radionuclide absorption and retention in tumors while minimizing uptake in healthy tissues, enabling precise diagnostic and therapeutic agents like nanobodies targeting HER2-positive cancers (e.g., iso-[131I]SGMIB-VHH_1028).[1][2] The company served oncology patients and developers of antibody-based therapies, addressing unmet needs in tumor-specific imaging and treatment; it was acquired by Solve Therapeutics, Inc. in June 2023, integrating its technology into SolveTx's oncology pipeline for expanded applications in patient selection and lifecycle management of therapeutics.[1]
A separate UK-based entity, Cereus Technologies Ltd, operated as an IT services and consulting firm focused on software development, data processing, and management consultancy but entered liquidation with overdue accounts as of 2023.[3][4] Given the query's description of "Cereius" as a technology company and the prominence of the biotech acquisition, this overview prioritizes Cereius, Inc.; the IT firm shows no evident growth momentum or ongoing operations.[3][4]
Cereius, Inc. emerged as a Duke University spin-out, co-founded by Professor Michael Zalutsky and Dr. Kimberly Lynn Blackwell around pioneering radiolabeling technology initially developed at the university and advanced by the Cereius team.[1] Zalutsky's expertise in radiochemistry and Blackwell's in oncology provided the foundational backing, with early investment from Mission BioCapital supporting the build-out of a site-specific conjugation chemistry platform.[1] Key milestones included preclinical progress on assets like CER-101 for brain cancer and HER2-targeted nanobodies, culminating in the June 2023 acquisition by Solve Therapeutics, which reunited it with experienced drug developers from VelosBio.[1][2]
In contrast, Cereus Technologies Ltd was incorporated in May 2019 in Southampton, UK, as a small IT consultancy with 7 employees, but it faced insolvency proceedings by 2023 without notable traction.[3][4]
(Note: Cereus Technologies Ltd lacked unique differentiators, operating generically in IT services before liquidation.[3][4])
Cereius, Inc. rode the wave of precision oncology and radiopharmaceuticals, a sector exploding with demand for targeted therapies amid rising cancer incidence and advances in radionuclide delivery.[1][2] Its timing aligned with post-2020 momentum in antibody-drug conjugates and theranostics (combined diagnostics/treatment), where improved chemistry addressed key limitations like poor tumor penetration in brain metastases—market forces favoring it included FDA approvals for similar platforms and Big Pharma's push into radioligand therapies.[1] By spinning out Duke tech and getting acquired by SolveTx, it influenced the ecosystem through tech transfer, enhancing antibody platforms for broader adoption and accelerating preclinical-to-clinical transitions in neuro-oncology.[1][2]
The unrelated Cereus Technologies Ltd played no discernible role, as a minor IT player amid UK tech consolidation.[3][4]
Post-acquisition, Cereius' platform lives on within Solve Therapeutics, likely advancing into clinical stages integrated with SolveTx's tumor-specific antibodies for HER2 and other targets, potentially yielding first-in-class radiotheranostics by 2026-2028.[1] Trends like AI-optimized radiolabeling, expanding nanobody use, and combination therapies with immunotherapies will shape its trajectory, amplifying SolveTx's pipeline value for partnerships or IPOs. Its influence may evolve from standalone innovator to foundational enabler in oncology precision medicine, validating academic spin-outs' role in high-stakes biotech—echoing its Duke origins as a model for targeted cancer breakthroughs.[1][2]
Cereius has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Series A in July 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2018 | $7.0M Series A | BDC Venture Capital, Domain Associates, Forbion, Mission BioCapital, RTW Investments |
